<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the management of lung disease in patients with cystic fibrosis&lt;sup&gt;[1-4]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the management of lung disease in patients with cystic fibrosis<sup>[1-4]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Overview of the management of lung disease in patients with cystic fibrosis<sup>[1-4]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Intervention</td> <td class="subtitle1">Indications/timing</td> <td class="subtitle1">Comments</td> </tr> <tr class="divider_bottom"> <td><strong>CFTR modulator</strong></td> <td> <ul> <li>Most patients, depending on genotype and age.</li> </ul> </td> <td> <ul> <li>Refer to UpToDate content and table on CFTR modulator therapy. The type of CFTR modulator and strength of recommendation depend on the genotype.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="3"><strong>Airway clearance therapies</strong></td> </tr> <tr> <td class="indent1">Inhaled DNase</td> <td rowspan="2"> <ul> <li>DNase and/or hypertonic saline are recommended for: <ul> <li>Patients with moderate to severe lung disease, including those on HEMT.</li> <li>Patients who are not on HEMT.</li> </ul> </li> <li>DNase is generally given once daily and hypertonic saline twice daily.</li> <li>Administer a short-acting bronchodilator before each treatment.</li> </ul> </td> <td rowspan="2"> <ul> <li>Expert opinion varies regarding thresholds for beginning these inhaled therapies. For those not on HEMT or with moderate to severe lung disease: <ul> <li>UpToDate suggests initiating DNase for patients with chronic respiratory symptoms or declining pulmonary function, while the CFF recommends its use for all children 2 years and older regardless of symptoms<sup>[3,4]</sup>.</li> <li>UpToDate suggests hypertonic saline for all age groups including infants, regardless of symptoms<sup>*</sup><sup>[5]</sup>, while the CFF recommends it for those 2 years and older<sup>[3,4]</sup>.</li> </ul> </li> <li>Regimen should be individualized, depending on patient preference and treatment burden (cost, time).</li> </ul> </td> </tr> <tr> <td class="indent1">Inhaled hypertonic saline</td> </tr> <tr class="divider_bottom"> <td class="indent1">Airway clearance physiotherapy (chest physiotherapy)</td> <td> <ul> <li>All patients who produce sputum, twice daily.</li> </ul> </td> <td> <ul> <li>No modality has been proven better than others.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="3"><strong>Prevention of infection</strong></td> </tr> <tr> <td class="indent1">Vaccinations</td> <td>All patients: <ul class="decimal_heading"> <li>Annual influenza vaccine.</li> <li>Pneumococcal vaccine, with PCV13 (or PCV15) and PPSV23, depending on age and prior immunization status<sup>[6]</sup>.</li> <li>All other routine childhood vaccines.</li> <li>COVID-19 vaccines, following CDC guidelines.</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">Palivizumab</td> <td> <ul> <li>We do not suggest prophylaxis with palivizumab for children with CF unless they have other indications.</li> </ul> </td> <td> <ul> <li>Insufficient evidence for benefit<sup>[7,8]</sup>.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Infection control measures</td> <td> <ul> <li>All patients, in all health care settings.</li> </ul> </td> <td> <ul> <li>Contact precautions, physical separation of patients, hand hygiene, use of masks by patients<sup>[3]</sup>.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="3"><strong>Bronchodilators</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1">Inhaled beta-2 adrenergic receptor agonist</td> <td> <ul> <li>All patients, before each dose of inhaled antibiotics, DNase, hypertonic saline, or airway clearance therapy session.</li> <li>As a rescue medication for acute symptoms, in patients with signs or symptoms of airway hyperresponsiveness.</li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td colspan="3"><strong>Antiinflammatory therapy</strong></td> </tr> <tr> <td class="indent1">Oral azithromycin</td> <td> <ul> <li>All patients ≥6 months, at time of acquisition of <em>P. aeruginosa</em><sup>*</sup>.</li> <li>Administered 3 times weekly.</li> <li>Do not give azithromycin to patients who are infected with nontuberculous mycobacteria.</li> </ul> </td> <td> <ul> <li>Evidence is strongest for patients ≥6 years who are infected with <em>P. aeruginosa</em><sup>[3,4]</sup> but is also effective for younger children when begun at the time that they first become infected with this organism<sup>[9]</sup>. Azithromycin is probably not effective for most patients who are not infected with <em>P. aeruginosa</em><sup>[10]</sup>.</li> <li>Benefits may be related to antiinflammatory and/or antibacterial properties.</li> </ul> </td> </tr> <tr> <td class="indent1">Ibuprofen (high-dose)</td> <td> <ul> <li>Suggested for children 6 to 17 years with good lung function (FEV<sub>1</sub> &gt;60% predicted)<sup>[3,4]</sup>.</li> <li>In clinical practice, this is not commonly used in the United States.</li> </ul> </td> <td> <ul> <li>Not recommended for patients with more severe lung function abnormalities or those who are older than 18 years of age. Requires pharmacokinetic studies to ensure proper dosing and monitoring for adverse effects (gastrointestinal bleeding, kidney function impairment).</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Inhaled glucocorticoids</td> <td> <ul> <li>Patients with definite signs and symptoms of asthma (including patients with asthmatic symptoms in the setting of ABPA)<sup>¶</sup>.</li> </ul> </td> <td> <ul> <li>Not recommended for patients without these characteristics, due to little evidence for benefit and concerns about adverse effects on growth.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="3"><strong>Prevention of acute exacerbations</strong></td> </tr> <tr> <td class="indent1">Inhaled tobramycin and/or aztreonam lysine</td> <td> <ul> <li>All patients with persistent <em>P. aeruginosa</em> infection.</li> <li>Give twice daily for 28 days, alternating with 28 days off of treatment.</li> </ul> </td> <td> <ul> <li>Refer to UpToDate content on antibiotic therapy for chronic pulmonary infection.</li> </ul> </td> </tr> <tr> <td class="indent1">Surveillance and early eradication of <em>P. aeruginosa</em></td> <td> <ul> <li>All patients without <em>P. aeruginosa</em> infection.</li> <li>Routine surveillance of sputum cultures or throat swabs, followed by eradication protocol if <em>P. aeruginosa</em> is detected.</li> </ul> </td> <td> <ul> <li>Refer to UpToDate content on early eradication of <em>P. aeruginosa</em>.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Neuraminidase inhibitor (eg, oseltamivir)</td> <td> <ul> <li>Selected patients meeting criteria for post-exposure prophylaxis or treatment.</li> </ul> </td> <td> <ul> <li>Refer to UpToDate content on seasonal influenza in children.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="3"><strong>Treatment of acute exacerbations</strong></td> </tr> <tr> <td class="indent1">Systemic antibiotics</td> <td> <ul> <li>All patients with an acute exacerbation.</li> </ul> </td> <td> <ul> <li>Selection of antibiotics is guided by cultures of respiratory secretions. Refer to UpToDate content on treatment of acute pulmonary exacerbations in cystic fibrosis.</li> </ul> </td> </tr> <tr> <td class="indent1">Intensify airway clearance therapies</td> <td> <ul> <li>All patients with an acute exacerbation.</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">Systemic glucocorticoids</td> <td> <ul> <li>Short course for patients with characteristics of an acute asthma episode. A prolonged course may be indicated for patients with confirmed acute ABPA<sup>¶</sup>.</li> </ul> </td> <td> <ul> <li>Although practice varies, UpToDate recommends against the use of systemic glucocorticoids except as noted.</li> </ul> </td> </tr> <tr> <td class="indent1">Respiratory support</td> <td> <ul> <li>As needed, guided by prognosis and patient preferences.</li> </ul> </td> <td> <ul> <li>Patient preferences should be established through discussions of advanced care directives, ideally occurring well before the patient requires the intervention.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>ABPA: allergic bronchopulmonary aspergillosis; 
        CDC: Centers for Disease Control and Prevention; 
        CF: cystic fibrosis; 
        CFF: Cystic Fibrosis Foundation; 
        CFTR: cystic fibrosis transmembrane conductance regulator; 
        COVID-19: coronavirus disease 2019; 
        DNase: dornase alfa; 
        FEV<sub>1</sub>: forced expiratory volume in 1 second; 
        HEMT: highly effective CFTR modulator therapy (eg, elexacaftor-tezacaftor-ivacaftor); 
        <em>P. aeruginosa</em>: <em>Pseudomonas aeruginosa</em>; 
        PCV13: pneumococcal conjugate vaccine (13-valent); 
        PCV15: pneumococcal conjugate vaccine (15-valent); 
        PPSV23: pneumococcal polysaccharide vaccine (23-valent).</p>
<p>* Suggestions from the UpToDate expert authors and editors, based on studies published after the 2013 guidelines from the CFF<sup>[8-10]</sup>.</p>
    
    ¶ Refer to UpToDate content on diagnosis and management of ABPA.</div><div class="graphic_reference">References:
    <ol>
<li>Lahiri T, Hempstead SE, Brady C, et al. Clinical practice guidelines from the Cystic Fibrosis Foundation for preschoolers with cystic fibrosis. Pediatrics 2016; 137:e20151784.</li>
<li>Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014; 35 Suppl 1:S1.</li>
<li>Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957.</li>
<li>Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013; 187:680.</li>
<li>Stahl M, Wielpütz MO, Ricklefs I, et al. Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled Study. Am J Respir Crit Care Med 2019; 199:1238.</li>
<li>Centers for Disease Control, pneumococcal vaccine recommendations. Available at: <a href="https://www.cdc.gov/vaccines/vpd/pneumo/hcp/recommendations.html" target="_blank">https://www.cdc.gov/vaccines/vpd/pneumo/hcp/recommendations.html</a>.</li>
<li>American Academy of Pediatrics (AAP) Committee on Infectious Diseases. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134:415.</li>
<li>Fink AK, Graff G, Byington CL, et al. Palivizumab and Long-term Outcomes in Cystic Fibrosis. Pediatrics 2019; 144.</li>
<li>Mayer-Hamblett N, Retsch-Bogart G, Kloster M, et al. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. Am J Respir Crit Care Med 2018; 198:1177.</li>
<li>Nichols DP, Odem-Davis K, Cogen JD, et al. Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. Am J Respir Crit Care Med 2020; 201:430.</li>
</ol></div><div id="graphicVersion">Graphic 119343 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
